Edward J. Dulac III
Net Worth
Last updated:
What is Edward J. Dulac III net worth?
The estimated net worth of Mr. Edward J. Dulac III is at least $4,904,182 as of 4 Mar 2024. He owns shares worth $115,666 as insider, has earned $2,883,516 from insider trading and has received compensation worth at least $1,905,000 in Fate Therapeutics, Inc..
What is the salary of Edward J. Dulac III?
Mr. Edward J. Dulac III salary is $476,250 per year as Chief Financial Officer & Principal Accounting Officer in Fate Therapeutics, Inc..
How old is Edward J. Dulac III?
Mr. Edward J. Dulac III is 50 years old, born in 1975.
What stocks does Edward J. Dulac III currently own?
As insider, Mr. Edward J. Dulac III owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Fate Therapeutics, Inc. (FATE) | Chief Financial Officer & Principal Accounting Officer | 101,479 | $1.14 | $115,666 |
What does Fate Therapeutics, Inc. do?
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Edward J. Dulac III insider trading
Fate Therapeutics, Inc.
Mr. Edward J. Dulac III has made 14 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 2,447 units of FATE stock worth $19,013 on 4 Mar 2024.
The largest trade he's ever made was exercising 19,460 units of FATE stock on 28 Sep 2021. As of 4 Mar 2024 he still owns at least 101,479 units of FATE stock.
Fate Therapeutics key executives
Fate Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Bahram Valamehr Ph.D. (48) Chief R&D Officer
- Mr. Edward J. Dulac III (50) Chief Financial Officer & Principal Accounting Officer
- Mr. J. Scott Wolchko (55) Founder, Chief Executive Officer, Pres & Director
- Ms. Cindy R. Tahl (52) Gen. Counsel & Corporation Sec.